Overview Dividends

(DVAX) Dynavax Technologies - Ratings and Ratios

Exchange: NASDAQ • Country: United States • Currency: USD • Type: Common Stock • ISIN: US2681582019

Vaccine, Infectious Diseases, Adjuvant, Immunotherapy, Allergy

DVAX EPS (Earnings per Share)

EPS Growth (3Y CAGR): -35.06%
EPS Trend (3Y Correlation): -15.7%

DVAX Revenue

Revenue Growth (3Y CAGR): -18.54%
Revenue Trend (3Y Correlation): -31.1%

Description: DVAX Dynavax Technologies August 19, 2025

Dynavax Technologies Corporation (NASDAQ:DVAX) is a biotechnology company listed on the NASDAQ stock exchange. As a common stock, DVAX is subject to market fluctuations and investor sentiment. The companys market capitalization stands at $1.24 billion, indicating a moderate size within the biotechnology sector.

The stocks price movement is characterized by a beta of 1.087, suggesting a slightly higher volatility compared to the overall market. With a forward Price-to-Earnings ratio of 29.24, investors are pricing in significant growth expectations, despite the companys current lack of profitability, as indicated by a Return on Equity of -9.16%. This suggests that investors are focusing on future potential rather than current earnings.

Key economic drivers for DVAX include the development and commercialization of its biotechnology products, particularly in the areas of immunotherapy and vaccine adjuvants. The companys financial performance is likely to be influenced by factors such as research and development expenses, clinical trial results, and regulatory approvals. Key Performance Indicators (KPIs) to watch include revenue growth, cash burn rate, and pipeline progress.

Investors should also consider the broader industry trends, including the growing demand for immunotherapy and vaccine adjuvants, as well as the competitive landscape within the biotechnology sector. With a relatively high forward P/E ratio, DVAXs stock price may be sensitive to changes in investor sentiment and expectations around the companys future performance.

DVAX Stock Overview

Market Cap in USD	1,153m
Sub-Industry	Biotechnology
IPO / Inception	2004-02-19

DVAX Stock Ratings

Growth Rating	-29.2%
Fundamental	40.9%
Dividend Rating	-
Return 12m vs S&P 500	-23.3%
Analyst Rating	4.0 of 5

DVAX Dividends

Currently no dividends paid

DVAX Growth Ratios

Growth Correlation 3m	-44.7%
Growth Correlation 12m	-73.2%
Growth Correlation 5y	15.8%
CAGR 5y	-2.98%
CAGR/Max DD 3y (Calmar Ratio)	-0.08
CAGR/Mean DD 3y (Pain Ratio)	-0.17
Sharpe Ratio 12m	0.89
Alpha	-26.04
Beta	1.129
Volatility	30.68%
Current Volume	1506.1k
Average Volume 20d	1251.5k
Stop Loss	9.9 (-3.9%)
Signal	-0.11

Piotroski VR‑10 (Strict, 0-10) 4.0

Net Income (-52.7m TTM) > 0 and > 6% of Revenue (6% = 19.0m TTM)

FCFTA 0.07 (>2.0%) and ΔFCFTA 3.72pp (YES ≥ +1.0pp, WARN ≥ +0.5pp)

NWC/Revenue 211.0% (prev 328.3%; Δ -117.3pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp)

CFO/TA 0.08 (>3.0%) and CFO 76.3m > Net Income -52.7m (YES >=105%, WARN >=100%)

NO Net Debt/EBITDA fails (EBITDA <= 0)

Current Ratio 6.65 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active)

Outstanding Shares last Quarter (138.4m) change vs 12m ago -10.43% (target <= -2.0% for YES)

Gross Margin 82.83% (prev 82.03%; Δ 0.80pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0)

Asset Turnover 32.69% (prev 24.57%; Δ 8.12pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0)

Interest Coverage Ratio -6.35 (EBITDA TTM -34.6m / Interest Expense TTM 6.74m) >= 6 (WARN >= 3)

Altman Z'' -1.44

(A) 0.73 = (Total Current Assets 785.7m - Total Current Liabilities 118.2m) / Total Assets 918.4m

(B) -1.07 = Retained Earnings (Balance) -980.7m / Total Assets 918.4m

warn (B) unusual magnitude: -1.07 — check mapping/units

(D) -2.31 = Book Value of Equity -979.9m / Total Liabilities 424.3m

Total Rating: -1.44 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D)

ValueRay F-Score (Strict, 0-100) 40.92

1. Piotroski 4.0pt = -1.0

2. FCF Yield 8.01% = 4.01

3. FCF Margin 20.89% = 5.22

4. Debt/Equity 0.58 = 2.34

5. Debt/Ebitda -5.39 = -2.50

6. ROIC - WACC (= -12.87)% = -12.50

7. RoE -9.16% = -1.53

8. Rev. Trend -31.13% = -2.34

9. EPS Trend -15.71% = -0.79

What is the price of DVAX shares?

As of October 30, 2025, the stock is trading at USD 10.30 with a total of 1,506,081 shares traded.
Over the past week, the price has changed by +3.36%, over one month by +8.28%, over three months by -7.35% and over the past year by -8.17%.

Is Dynavax Technologies a good stock to buy?

No, based on ValueRay´s Fundamental Analyses, Dynavax Technologies (NASDAQ:DVAX) is currently (October 2025) a stock to sell. It has a ValueRay Fundamental Rating of 40.92 and therefor a negative outlook according to the companies health.
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of DVAX is around 9.25 USD . This means that DVAX is currently overvalued and has a potential downside of -10.19%.

Is DVAX a buy, sell or hold?

Dynavax Technologies has received a consensus analysts rating of 4.00. Therefore, it is recommended to buy DVAX.

Strong Buy: 2
Buy: 1
Hold: 0
Sell: 1
Strong Sell: 0

What are the forecasts/targets for the DVAX price?

Issuer	Target	Up/Down from current
Wallstreet Target Price	22.8	121.4%
Analysts Target Price	22.8	121.4%
ValueRay Target Price	10.3	-0.1%

DVAX Fundamental Data Overview October 20, 2025

Market Cap USD = 1.15b (1.15b USD * 1.0 USD.USD)
P/E Forward = 29.2398
P/S = 3.6448
P/B = 2.3968
Beta = 1.129
Revenue TTM = 316.3m USD
EBIT TTM = -42.8m USD
EBITDA TTM = -34.6m USD
Long Term Debt = 220.8m USD (from longTermDebt, last quarter)
Short Term Debt = 44.1m USD (from shortTermDebt, last quarter)
Debt = 285.5m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 186.4m USD (from netDebt column, last quarter)
Enterprise Value = 824.5m USD (1.15b + Debt 285.5m - CCE 613.7m)
Interest Coverage Ratio = -6.35 (Ebit TTM -42.8m / Interest Expense TTM 6.74m)
FCF Yield = 8.01% (FCF TTM 66.1m / Enterprise Value 824.5m)
FCF Margin = 20.89% (FCF TTM 66.1m / Revenue TTM 316.3m)
Net Margin = -16.67% (Net Income TTM -52.7m / Revenue TTM 316.3m)
Gross Margin = 82.83% ((Revenue TTM 316.3m - Cost of Revenue TTM 54.3m) / Revenue TTM)
Gross Margin QoQ = 85.29% (prev 79.80%)
Tobins Q-Ratio = 0.90 (Enterprise Value 824.5m / Total Assets 918.4m)
Interest Expense / Debt = 0.57% (Interest Expense 1.64m / Debt 285.5m)
Taxrate = 11.76% (2.50m / 21.2m)
NOPAT = -37.7m (EBIT -42.8m * (1 - 11.76%)) [loss with tax shield]
Current Ratio = 6.65 (Total Current Assets 785.7m / Total Current Liabilities 118.2m)
Debt / Equity = 0.58 (Debt 285.5m / totalStockholderEquity, last quarter 494.2m)
Debt / EBITDA = -5.39 (negative EBITDA) (Net Debt 186.4m / EBITDA -34.6m)
Debt / FCF = 2.82 (Net Debt 186.4m / FCF TTM 66.1m)
Total Stockholder Equity = 575.8m (last 4 quarters mean from totalStockholderEquity)
RoA = -5.74% (Net Income -52.7m / Total Assets 918.4m)
RoE = -9.16% (Net Income TTM -52.7m / Total Stockholder Equity 575.8m)
RoCE = -5.37% (EBIT -42.8m / Capital Employed (Equity 575.8m + L.T.Debt 220.8m))
RoIC = -4.61% (negative operating profit) (NOPAT -37.7m / Invested Capital 818.0m)
WACC = 8.26% (E(1.15b)/V(1.44b) * Re(10.18%) + D(285.5m)/V(1.44b) * Rd(0.57%) * (1-Tc(0.12)))
Discount Rate = 10.18% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 33.33 | Cagr: 1.89%
[DCF Debug] Terminal Value 63.99% ; FCFE base≈53.8m ; Y1≈39.0m ; Y5≈21.7m
Fair Price DCF = 2.56 (DCF Value 299.7m / Shares Outstanding 117.3m; 5y FCF grow -32.46% → 3.0% )
EPS Correlation: -15.71 | EPS CAGR: -35.06% | SUE: -2.72 | # QB: 0
Revenue Correlation: -31.13 | Revenue CAGR: -18.54% | SUE: 1.46 | # QB: 1

Additional Sources for DVAX Stock

News: Wall Street Journal | Benzinga | Yahoo Finance
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle